# Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

> **NCT03644056** · PHASE1 · COMPLETED · sponsor: **ImmuneOncia Therapeutics Inc.** · enrollment: 15 (actual)

## Conditions studied

- Solid Tumor
- Metastasis
- Locally Advanced

## Interventions

- **DRUG:** IMC-001

## Key facts

- **NCT ID:** NCT03644056
- **Lead sponsor:** ImmuneOncia Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2019-02-15
- **Final completion:** 2020-05-14
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03644056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03644056, "Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03644056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*